With a Phase III program in full swing for its insomnia drug Indiplon (formerly NBI-34060), Neurocrine Biosciences Inc. unveiled full Phase II data for the first time during the meeting of the Associated Professional Sleep Societies earlier this month in Chicago. (BioWorld Financial Watch)

"What we do in coronary artery disease is control the disease," he said. "We put stents in, we operate on patients, we give blood pressure-lowering agents. We use a multi-modality approach."